NCT07219875 Training Reward Responsiveness Through Virtual Reality
| NCT ID | NCT07219875 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of California, Los Angeles |
| Condition | Positive Affect |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-07-08 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 80 participants in total. It began in 2025-07-08 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to compare the effects of Virtual Reality-Reward Training (VR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.
Eligibility Criteria
Inclusion Criteria: 1. At least 18 years old 2. Fluent in written and spoken English 3. Meet all of the following dimensional score cutoffs: 1. Score on the DASS-21 depression subscale must be ≥ 8 2. Score on the PANAS-P of 27 or lower 3. Score on the WSAS of ≥ 11 Exclusion Criteria: 1. Lifetime history of bipolar disorder, psychosis, mental retardation, or organic brain damage 2. Substance use disorder in the past 6 months 3. Current use of psychotropic medications 4. Currently pregnant or planning to become pregnant 5. Self-reported frequent motion sickness 6. Self-reported seizures within the last year and/or a diagnosis of epilepsy
Frequently Asked Questions
Who can join the NCT07219875 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Positive Affect. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07219875 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07219875 currently recruiting?
Yes, NCT07219875 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of California, Los Angeles to inquire about joining.
Where is the NCT07219875 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT07219875 clinical trial?
NCT07219875 is sponsored by University of California, Los Angeles. The trial plans to enroll 80 participants.